Next Article in Journal
Immune Checkpoints as a Target for Colorectal Cancer Treatment
Next Article in Special Issue
Integrity and Quantity of Total Cell-Free DNA in the Diagnosis of Thyroid Cancer: Correlation with Cytological Classification
Previous Article in Journal
Development of a High-Density SNP-Based Linkage Map and Detection of QTL for β-Glucans, Protein Content, Grain Yield per Spike and Heading Time in Durum Wheat
Previous Article in Special Issue
Differentiated Thyroid Cancer—Treatment: State of the Art

New Insights in Thyroid Cancer and p53 Family Proteins

Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy
Endocrinology, Department of Clinical and Experimental Medicine, Garibaldi Nesima Medical Center, University of Catania, 95122 Catania, Italy
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2017, 18(6), 1325;
Received: 10 April 2017 / Revised: 16 June 2017 / Accepted: 17 June 2017 / Published: 21 June 2017
(This article belongs to the Special Issue Current Knowledge in Thyroid Cancer—From Bench to Bedside)
Thyroid cancers are common endocrine malignancies that comprise tumors with different clinical and histological features. Indeed, papillary and follicular thyroid cancers are slow-growing, well-differentiated tumors, whereas anaplastic thyroid cancers are undifferentiated neoplasias that behave much more aggressively. Well-differentiated thyroid carcinomas are efficiently cured by surgery and radioiodine, unlike undifferentiated tumors that fail to uptake radioactive iodine and are usually resistant to chemotherapy. Therefore, novel and more effective therapies for these aggressive neoplasias are urgently needed. Whereas most genetic events underlying the pathogenesis of well-differentiated thyroid cancers have been identified, the molecular mechanisms that generate undifferentiated thyroid carcinomas are still unclear. To date, one of the best-characterized genetic alterations leading to the development of poorly differentiated thyroid tumors is the loss of the p53 tumor suppressor gene. In addition, the existence of a complex network among p53 family members (p63 and p73) and their interactions with other factors that promote thyroid cancer progression has been well documented. In this review, we provide an update on the current knowledge of the role of p53 family proteins in thyroid cancer and their possible use as a therapeutic target for the treatment of the most aggressive variants of this disease. View Full-Text
Keywords: thyroid cancer; p53; p63; p73; genetic alterations; p53 inhibition mechanisms; target therapies thyroid cancer; p53; p63; p73; genetic alterations; p53 inhibition mechanisms; target therapies
Show Figures

Graphical abstract

MDPI and ACS Style

Manzella, L.; Stella, S.; Pennisi, M.S.; Tirrò, E.; Massimino, M.; Romano, C.; Puma, A.; Tavarelli, M.; Vigneri, P. New Insights in Thyroid Cancer and p53 Family Proteins. Int. J. Mol. Sci. 2017, 18, 1325.

AMA Style

Manzella L, Stella S, Pennisi MS, Tirrò E, Massimino M, Romano C, Puma A, Tavarelli M, Vigneri P. New Insights in Thyroid Cancer and p53 Family Proteins. International Journal of Molecular Sciences. 2017; 18(6):1325.

Chicago/Turabian Style

Manzella, Livia; Stella, Stefania; Pennisi, Maria S.; Tirrò, Elena; Massimino, Michele; Romano, Chiara; Puma, Adriana; Tavarelli, Martina; Vigneri, Paolo. 2017. "New Insights in Thyroid Cancer and p53 Family Proteins" Int. J. Mol. Sci. 18, no. 6: 1325.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop